EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial

SAB Biotherapeutics Inc SABS has revealed topline results from the Phase 3 National Institutes of Health's (NIH) ACTIV-2 trial that assessed SAB-185 in non-hospitalized COVID-19 patients at high risk for severe outcomes. 

What Happened: SAB-185 demonstrated benefit in sustained symptom resolution of COVID-19 caused by Omicron compared to participants who received a monoclonal antibody cocktail, REGEN-COV, developed by Regeneron Pharmaceuticals Inc REGN and Roche Holdings AG RHHBY.

Also Read: EXCLUSIVE: SAB Biotherapeutics Secures FDA Breakthrough Therapy Tag For Its Influenza Immunotherapy.

Data Results: 66% of participants treated with SAB-185 reached full symptom resolution for at least four consecutive days by Day 28, while only 50% of participants on REGEN-COV met this endpoint (p=0.010).

The median time to symptom resolution for at least four consecutive days was seven days shorter for SAB-185. 

Also, the median time to symptom resolution for at least two consecutive days was six days shorter for SAB-185 than those treated with REGEN-COV (p=0.021). 

In the non-Omicron population, the median time to symptom resolution for at least four consecutive days was seven days shorter for SAB-185, and the median time to symptom resolution for at least two consecutive days was four days shorter for SAB-185 than REGEN-COV. 

However, neither of these analyses met statistical significance.

Why It Matters: Last March, SAB Biotherapeutics said that due to low hospitalization and death rates in the trial, the National Institutes of Health's NIH ACTIV-2 Program discontinued enrollment in its Phase 3 COVID-19 trial.

The sponsors concluded that the potential efficacy of SAB 185 would not be possible to demonstrate statistically significant clinical efficacy with the existing study design.

"The ACTIV-2 data further validates the potential of SAB's platform. It shows that the DiversitAb™ platform can open the door to treatments that are potentially more effective and potent and which remain efficacious over longer periods versus monoclonal antibodies," said Eddie J. Sullivan, co-founder, President & CEO of SAB Biotherapeutics

Price Action: SABS shares closed at $0.78 on Tuesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMarket-Moving ExclusivesExclusives
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!